Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| HUTCHMED (China) Limited | Fruquintinib (HMPL-013) - (FRESCO-2) | Metastatic Colorectal Cancer | Phase 3 | Data Released | Oral | Oncology |
| HUTCHMED (China) Limited | Fruquintinib - (FRESCO) | Metastatic colorectal cancer (CRC) | Phase 3 | Data Released | Oral | Oncology |
| HUTCHMED (China) Limited | IMG-007 - (ADAPTIVE) | Atopic dermatitis and other immunological diseases | Phase 2b | Ongoing | intravitreal | Immunology |
| HUTCHMED (China) Limited | Savolitinib | Gastric cancer (GC) and gastroesophageal junction adenocarcinomas (GEJ) | Phase 2 | Data Released | Oral | Oncology |
| HUTCHMED (China) Limited | HMPL-306 - (RAPHAEL) | Relapsed / refractory acute myeloid leukemia (AML) | Phase 3 | Ongoing | Oral | Oncology |
| HUTCHMED (China) Limited | Fruquintinib in combination with Sintilimab - (FRUSICA-2) | 2L renal cell carcinoma | Phase 2/3 | Data Released | Oral and intravenous | Oncology |
| HUTCHMED (China) Limited | Savolitinib + TAGRISSO (osimertinib) - (SAVANNAH) | Non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | Oral | Oncology |
| HUTCHMED (China) Limited | SULANDA (surufatinib) and TUOYI (toripalimab) - (SURTORI-01) | Neuroendocrine carcinoma | Phase 3 | Ongoing | Oral for SULANDA surufatinib intravenous for TUOYI toripalimab | Oncology |
